| Protein engineering strategies for improved pharmacokinetics A Rondon, S Mahri, F Morales‐Yanez, M Dumoulin, R Vanbever Advanced Functional Materials 31 (44), 2101633, 2021 | 40 | 2021 |
| The influence of organic modification on the cytotoxicity of clay particles to keratinocytes, hepatocytes and macrophages; an investigation towards the safe use of polymer-clay … M Connolly, Y Zhang, S Mahri, DM Brown, N Ortuño, M Jordá-Beneyto, ... Food and Chemical Toxicology 126, 178-191, 2019 | 18 | 2019 |
| Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice S Mahri, A Rondon, T Wilms, C Bosquillon, R Vanbever Journal of Controlled Release 329, 1054-1065, 2021 | 15 | 2021 |
| PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages S Mahri, E Hardy, T Wilms, H De Keersmaecker, K Braeckmans, ... International journal of pharmaceutics 593, 120107, 2021 | 9 | 2021 |
| PEGylation of Recombinant Human Deoxyribonuclease I Provides a Long‐Acting Version of the Mucolytic for Patients with Cystic Fibrosis MJ Guichard, T Wilms, S Mahri, HP Patil, D Hoton, B Ucakar, ... Advanced Therapeutics 4 (2), 2000146, 2021 | 7 | 2021 |
| Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: a technical feasibility study S Mahri, T Wilms, P Hagedorm, MJ Guichard, K Vanvarenberg, ... European Journal of Pharmaceutical Sciences 189, 106522, 2023 | 6 | 2023 |
| Production and characterization of mono-PEGylated alpha-1 antitrypsin for augmentation therapy X Liu, K Vanvarenberg, KGW Kouassi, S Mahri, R Vanbever International journal of pharmaceutics 612, 121355, 2022 | 5 | 2022 |
| Impact of protein aggregation on the immunogenicity of a human monoclonal antibody following pulmonary administration in mice S Mahri, C Cassiers, S Gracin, D Tyteca, F Uwambayinema, F Huaux, ... International Journal of Pharmaceutics 667, 124880, 2024 | | 2024 |
| PEGYLATION OF RHDNASE PROVIDES A LONG-ACTING VERSION OF THE MUCOLYTIC FOR PATIENTS WITH CYSTIC FIBROSIS THAT CAN SIGNIFICANTLY REDUCE TREATMENT BURDEN T Wilms, S Mahri, A Rondon, C Bosquillon, R Vanbever JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY 34 (5), A20-A21, 2021 | | 2021 |
| Mechanisms of retention of PEGylated recombinant human deoxyribonuclease i (rhDNase) in the lungs S Mahri Université Catholique de Louvain and University of Nottingham, 2020 | | 2020 |
Rita VanbeverUniversité catholique de Louvain在 uclouvain.be 的电子邮件经过验证
